Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia

Cardiovascular Risk and DiseasesLipid-Lowering Drugs

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

Lancet Diabetes Endocrinol.

Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA

doi: 10.1016/S2213-8587

RECOMMENDED

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Atherosclerosis.

Pasta A, Cremonini AL, Formisano E, Fresa R, Bertolini S, Pisciotta L

doi: 10.1016/j.atherosclerosis.2020.07.006.

RECOMMENDED

Lipid-Lowering Drugs

Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program

Atherosclerosis.

Farnier M, Hovingh GK, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, Manvelian G, Guyton JR

doi: 10.1016/j.atherosclerosis.

Heart, Artery and Coronary Diseases

D-dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events and Cancer in Stable Coronary Heart Disease Patients: The LIPID Study

Circulation.

Simes J, Robledo KP, White HD, Espinoza D, Stewart RA, Sullivan DR, Zeller T, Hague W, Nestel PJ, Glasziou PP, Keech AC, Elliott J, Blankenberg S, Tonkin AM; LIPID study investigators

doi: 10.1161/CIRCULATIONAHA.

RECOMMENDED

Heart, Artery and Coronary DiseasesLipid-Lowering Drugs

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

J Am Coll Cardiol.

Santos RD, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, López JAG, Bray S, Kurtz CE, Hamer AW, Raal FJ

doi: 10.1016/j.jacc.2019.12.020.

Cardiovascular Risk and Diseases

Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial

JAMA Cardiol.

Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Ørsted DD, Nauck MA

doi: 10.1001/jamacardio.2019.3080.

Cardiac Arrest or Death

Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity

JAMA Pediatr

Tidblad A, Bottai M, Kieler H, Albertsson-Wikland K, Sävendahl L

doi: 10.1001/jamapediatrics.2020.5199

Myocardial Infarction

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Lancet.

Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group

doi: 10.1016/

Cardiovascular Risk and Diseases

Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes

J Am Coll Cardiol.

D'Erasmo L, Minicocci I, Nicolucci A, Pintus P, Roeters Van Lennep JE, Masana L, Mata P, Sánchez-Hernández RM, Prieto-Matos P, Real JT, Ascaso JF, Lafuente EE, Pocovi M, Fuentes FJ, Muntoni S, Bertolini S, Sirtori C, Calabresi L, Pavanello C, Averna M, Cefalu AB, Noto D, Pacifico AA, Pes GM, Harada-Shiba M, Manzato E, Zambon S, Zambon A, Vogt A, Scardapane M, Sjouke B, Fellin R, Arca M

doi: 10.1016/j.jacc.2017.11.028.

Related content

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies

Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program

D-dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events and Cancer in Stable Coronary Heart Disease Patients: The LIPID Study

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial

Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes